196 results about "Uricacidemia" patented technology

The invention belongs to the field of medicinal chemistry and particularly relates to hURAT1 (human urate anion transporter 1) inhibitors and an application thereof. Specifically, the hURAT1 inhibitors are compounds with structure shown as formula (I) or (II) in the description or pharmaceutically acceptable salts of the compounds. Experiments prove that the compounds have good inhibition effect on uric acid transport of the hURAT1 in an HEK293 transfection cell, which shows that the compounds have good application prospect in treatment of hyperuricemia or gout.

The invention discloses an application of a folium eucalypti extractive serving as an active ingredient in preparation of medicines for treating hyperuricemia, and also provides a preparation method of the folium eucalypti extractive. Main active ingredients of the folium eucalypti extractive are 6-12% of scabish essence B, 1-2% of tellimagrandin I, 1-1.5% of quercetin-3-O-glucoside acid, 0.8-1.2% of ellagic acid, 0.2-0.5% of tellimagrandin II, 0.1-0.15% of 1,2,3,4,6 pentagalloylglucose and 25-50% of total phenols. The pharmacological experiment shows that the folium eucalypti extractive has an inhibiting effect on xanthine oxidase and relatively strong effects of reducing uric acid, protecting renal injury caused by the hyperuricemia and the like in bodies.

The invention provides a composition and application of the composition in the preparation of medicaments, health-care food or functional food for preventing and treating hyperuricemia. The composition comprises at least one of holothuria saponins and holothuria polysaccharides, wherein the holothuria saponins are main secondary metabolites in holothuria, and have various physiological and pharmacological activity of hemolysis, fungus resistance, cytotoxicity, tumor resistance, immunoregulation, antioxidation, blood fat reduction and the like and have high medicinal value; the holothuria polysaccharides are important ingredients of holothuria body walls, and have the pharmacological activity of anticoagulation, thrombus resistance, tumor resistance, immunoregulation and the like. Animal experiments prove that the prepared composition containing at least one of the holothuria saponins and the holothuria polysaccharides can improve the serum uric acid level of animals in vivo obviously so as to prevent and treat the hyperuricemia.

The invention belongs to the chemical field of natural products and in particular relates to an extraction method and an application of moringa oleifera leaf total flavones. The extraction method adopts microwave and ultrasound to synergistically extract the moringa oleifera leaf total flavones, and has the advantages of high efficiency, time saving, energy conservation, low energy consumption, simple operation and good repeatability. Besides, an animal test proves that the extracted moringa oleifera leaf total flavones have a significant treatment effect on hyperuricosuria and Alzheimer's disease. The total flavones provided by the invention can reduce uric acid, and can also reduce cholesterol, triacylglycerol, urea nitrogen, creatinine and xanthine oxidase, reduce the generation of uric acid, directly decompose uric acid, improve the renal function, promote uric acid excretion, and protect multiple levels of blood vessels to reduce uric acid, so that the moringa oleifera leaf total flavones are beneficial for healing of lithemia patients and have a broad medical application prospect.

Methods and compositions for treating and / or preventing hyperuricemia or metabolic disorders associated with hyperuricemia comprising administering to a patient in need a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.

The present application discloses stable pharmaceutical compositions for the oral administration of febuxostat with pharmaceutical excipients which provide improved dissolution rate and polymorphic stability both while manufacturing and during storage and process for preparing the stable compositions, packaging and their use in the treatment of gout of hyperuricemia.

The present invention provides a drug for treating hyperuricemia and gout, ie., evodiamine dispersion tablets. The evodiamine dispersion tablets are the preparation prepared from the following raw materials and additives, by weight, 7-13 parts of evodiamine, 30-50 parts of a solid dispersion water-soluble carrier material, 70-90 parts of a filler, and 8-14 parts of a disintegrating agent. The present invention further provides a preparation method and uses of the dispersion tablets. The evodiamine dispersion tablets of the present invention have characteristics of short disintegration time and high dispersion uniformity. According to the present invention, the dissolution of the insoluble drug evodiamine in the solid preparation can be significantly improved, the absorption of the evodiamine in the human body is prompted, the bioavailability of the drug is increased, and new selections are provided for clinical medication for treatments of hyperuricemia and gout.

The invention provides a DNA tetrahedron-resveratrol compound as well as a preparation method and application thereof, and belongs to the technical field of medicines. The compound is a compound formed by mixing DNA tetrahedral framework nucleic acid and resveratrol. The DNA tetrahedron-resveratrol compound can effectively reduce body weight and blood sugar content and improve tolerance to glucose and insulin, so that obesity is effectively treated, and insulin resistance caused by obesity is improved and even treated; the compound can also be used for treating metabolic syndrome, type 2 diabetes mellitus, hypertension, hyperuricemia, dyslipidemia, cardiovascular and cerebrovascular diseases, polycystic ovarian syndrome, Alzheimer's disease or tumor and other diseases caused by insulin resistance. Meanwhile, the compound disclosed by the invention can be used for effectively treating adipose tissue inflammation. Compared with single use of DNA tetrahedral framework nucleic acid or resveratrol, the compound disclosed by the invention plays a synergistic effect and has a good application prospect.

Provided is a triarylcarboxylic acid derivative, or an isomer, a prodrug, a hydrate, a solvate, a polymorph, or a pharmaceutically acceptable salt thereof, represented by the following general formula (I):wherein A is an optionally substituted aryl or heteroaryl, and B is an optionally substituted monocyclic heteroaryl; and a pharmaceutical composition comprising the same and a pharmaceutically acceptable carrier. The triarylcarboxylic acid derivative (I) exhibits potent xanthine oxidase inhibiting action and is therefore useful as a therapeutic agent for preventing or treating hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy and diabetic retinopathy.

The invention discloses a hematuria-reducing lactic acid bacteria strain and a screening method and application thereof in preparation of functional yoghourt. The strain is characterized in that the lactic acid bacteria strain is classified and named as Lactobacillus brevis PDD-5 strain, is preserved in China General Microbiological Culture Collection Center on August 31, 2020, and has a preservation number of CGMCC No. 20573. The screening method comprises the following steps of (1), selecting traditional fermented food pickles as samples, and carrying out preliminary screening and separationpurification on lactic acid bacteria; and (2), obtaining strains with negative catalase activity and positive gram staining, then culturing and collecting thalli, re-suspending the thalli in an inosine guanosine solution and culturing, and then selecting lactic acid bacteria with the highest degradation rate on inosine or guanosine. The method has the advantages of oxidation resistance, inflammation resistance, immunoregulation, blood uric acid reduction, capability of relieving and treating hyperuricemia and the like.

The invention belongs to the field of medicinal chemistry, and in particular relates to a URT1 inhibitor for promoting uric acid excretion, which is a compound represented by the structure of the formula (I) or a pharmaceutically acceptable salt thereof. Experiments show that the compound provided by the invention has excellent inhibitory effect to hURAT1 transport uric acid in HEK293 transfectedcells and has a good application prospect in treatment of hyperuricemia or gout. The formula (I) is shown in the description.

The invention discloses an application of Bacillus coagulans in the preparation of a blood uric acid lowering preparation. The application is concretely characterized in that the Bacillus coagulans isused to lower the blood uric acid and prevent or treat hyperuricemia, gout and gout complications.

The invention discloses a medicinal use of phyllanthus emblica extract and particularly relates to application of the phyllanthus emblica extract to preparing a drug for treating hyperuricemia. The phyllanthus emblica has an effect of treating the hyperuricemia, can be used for effectively lowering uric acid content in blood and can achieve good curative effects of treating hyperuricemia-associated metabolic diseases of acute gout, chronic gout, gouty arthritis, gout flare, uratic renal lithiasis, gouty nephropathy and the like.

The invention provides an application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases. Provided evidences indicate that the Erding granules have new application of obviously preventing and treating hyperuricemia and gout diseases. The Erding granules are disclosed to have obvious hypouricemic effect, so as to reduce serum uric acid values of hyperuricemia and gout diseases and alleviate clinical symptoms of patients with gout.

The invention discloses an application of elaeagnus conferta roxb, namely the application of the elaeagnus conferta roxb in preparation of drugs for treating kidney stones, gall-stone and hyperuricemia. In the treatment of the kidney stones, the drug is used for reducing the rate of the kidney stones, improving kidney coefficient, reducing calcium content of the kidney, reducing serum urea nitrogen and reducing serum creatinine. In the treatment of the gall-stone, the elaeagnus conferta roxb is used for treating bile pigment gallstones and cholesterol gallstones; preferably in the treatment of bilirubin gallstones, the elaeagnus conferta roxb is used for reducing the rate of the gallbladder stones, calcium ion content in bile, total bilirubin concentration and free bilirubin concentration in the treatment of the bile pigment gallstones; in the treatment of the cholesterol gallstones, the elaeagnus conferta roxb is used for reducing the rate of the gallbladder stones and the cholesterol content in the bile; and in the treatment of hyperuricemia, the elaeagnus conferta roxb is used for reducing uric acid content in serum. The application of the elaeagnus conferta roxb can be spread to related products of the elaeagnus conferta roxb; and the related product includes a fruit aqueous extract of the elaeagnus conferta roxb, dewatered elaeagnus conferta roxb, capsules, troches, granulas, fruit vinegar, jam and fruit juice.